The Regulatory Agency Interaction Plan: A Tool for Biotech Leaders
A biotech is six weeks from a Type B end-of-phase meeting with FDA. The briefing document is being finalized. The questions are formatted correctly. The team knows the procedural requirements. And in the pre-meeting internal review, it becomes clear that the clinical lead and the regulatory lead have different views on the primary objectives of the meeting. The clinical team wants FDA's input on an endpoint question. The regulatory lead needs FDA's alignment on the overall development plan before the next financing. The CMC team has a manufacturing question they want to add to the agenda. Each concern is legitimate. But the agency meeting is in six weeks.
The preparation was thorough on paper. The strategic work, deciding what the company needs from this meeting, what it will do if the agency pushes back, and how this interaction connects to the next one, was never done.
That scenario is more common than it should be. It is the default outcome when the regulatory interaction plan does not exist.
In brief: Meeting preparation and meeting readiness are not the same thing. The strategic work; what the company needs from the interaction, what it will do if the agency pushes back, how this meeting sets up the next one; happens months before the briefing document is written. The document is the output of the strategy, not the occasion for building it. A company that conflates the two will find out the difference in the quality of feedback it receives.
What an Agency Interaction Plan Actually is
The interaction plan is a forward-looking map of every planned agency touchpoint across the development lifecycle, with a clear strategic purpose assigned to each one. It defines what the company needs from each interaction, what fallback positions it holds if the agency pushes back, and how each touchpoint sets up the next one. These are strategic questions that require months of upstream thinking, not six weeks of document assembly.
The interaction plan also forces internal alignment before external engagement. A company with unresolved internal disagreements about what the meeting is for should not yet have filed the meeting request. Surfacing disagreements early enough to resolve them is the value of an interaction plan.
By the time the briefing document is being finalized, the strategic positions should already be settled. The document is the output of the strategy, not the occasion for building it.
How the FDA and the EMA Agency Engagement Work Differently
FDA's formal meeting structure; Type A, Type B, Type C meetings with defined timelines, written responses, and procedural expectations, is built around a transactional model. The sponsor submits questions. The agency responds within defined timeframes. The meeting is a structured exchange within a procedural framework. That structure is useful, but it can create a false sense of readiness. A company can meet all the procedural requirements for a Type B meeting, submit a technically complete briefing document, and walk out of the meeting with minutes that advance nothing, because the strategic work that makes a meeting productive was never done.
EMA's scientific advice process works differently. It is more iterative and more consultative. The agency engages with the development strategy as a whole, not just a set of discrete questions. The rapporteur relationship matters. The way the evidence is framed in the briefing document shapes the kind of dialogue the company gets. Companies that approach EMA scientific advice the way they approach an FDA Type B meeting tend to get generic feedback. This is the agency's way of signaling that it could not find the strategy in what was presented, and acting on generic feedback is substantially more expensive than having entered the meeting with a sharper ask.
The FDA and the EMA require different preparation frameworks, different question architectures, and different internal alignment processes. A single interaction approach applied to both agencies produces weaker, less actionable feedback from each.
Why Internal Misalignment is the Biggest Risk Before a Major Agency Meeting
The most common failure mode in agency meeting preparation is not inadequate documents. It is internal misalignment that the agency can see. When the clinical narrative, the CMC plan, and the regulatory strategy are not telling a coherent story, regulators notice and they respond by being more cautious, more questioning, and less willing to give the directional feedback that makes a meeting valuable.
When the nonclinical teams’ proposed studies, clinical team's endpoint rationale, or when the CMC team's timeline assumptions are inconsistent the regulatory team's data needs to support a chosen accelerate pathway are not in alignment with the phase of clinical development, the meeting is at risk of losing coherence. Agencies are experienced at reading whether a sponsor has a settled strategy. Incoherence signals that it does not, and the feedback a company receives in that condition tends to be cautious and hedged rather than directional.
This pattern has documented consequences at the submission stage. A January 2025 summary of a public FDA meeting, published by the Duke-Margolis Institute for Health Policy, reported that FDA has observed a potential decline in initial biologics submission quality, with CMC deficiencies as a leading driver of Complete Response Letters.
The interaction plan is the mechanism for resolving those questions internally, early enough that they do not become the deficiencies that stall a submission. When nonclinical, clinical, CMC, and regulatory are aligned on what the company needs from the interaction, the agency gets a coherent narrative and a clear ask. The directional feedback that follows is worth substantially more than cautious hedging from an agency that sensed the strategy had not been settled.
What Building a Regulatory Interaction Plan Looks Like in Practice
The interaction plan starts with the sequence of meetings across the development lifecycle and works backward: what does the company need from each interaction, and what needs to be true internally before it enters the room? A pre-IND meeting with FDA is the first chapter in a regulatory relationship that will span years. The questions the company asks, and the positions it takes, will shape how the agency thinks about the program going forward.
Each interaction is a chapter in a longer narrative. When that narrative is not actively managed, it shows in the agency's feedback. It is less specific, less directional, and harder to act on. An agency that has followed a coherent regulatory story across multiple interactions engages differently than one that is reconstructing the program's logic from scratch at each meeting.
This is especially true for programs with expedited designations. These pathways exist to enable earlier and more substantive agency dialogue.
A company that does not use that access strategically, with a clear ask and a narrative the agency can follow, is wasting the most valuable interactions available to it.
The plan also needs to account for the parallel Health Technology Assessment (HTA) dimension that now applies to most global programs. Under the EU HTA Regulation, EMA scientific advice can now be sought in parallel with HTA joint scientific consultation, a process that requires the company to address both regulatory and comparative effectiveness questions simultaneously. Companies not building this into their interaction planning will arrive at EMA scientific advice with a strategy that answers the regulatory questions but not the HTA ones, and that gap will surface in the Joint Clinical Assessment when the clinical program is already locked.
The questions the company asks in a pre-IND meeting or a scientific advice procedure should trace directly back to the evidence gaps the TPP has identified and the regulatory risk priorities the program has mapped. These are the places where the company needs agency alignment before the next development decision is made. When that connection is explicit, the agency gets questions it can answer with precision. When it is not, the agency gets questions that are technically valid but strategically disconnected, and the feedback reflects that.
The companies that get the most value from pivotal FDA and EMA interactions typically arrive with:
- Internal alignment
- A clear ask
- A narrative that connects the science to the regulatory pathway to the commercial case
By that stage, the work the meeting requires has already been done. The meeting becomes a test of strategy rather than an occasion for discovering what should have been resolved months earlier. The difference in outcome across timelines, financing alignment, and agency relationships, can be substantial. SSI Strategy works with biotech teams to build the interaction planning discipline that makes high-stakes agency moments productive rather than expensive.
If you are approaching a major FDA or EMA interaction and want to make sure the strategy behind the meeting is as strong as the documents in front of it, explore how SSI helps biotech teams prepare for high-stakes agency engagement.
Related reading
Explore our Regulatory Strategy Offering:
Regulatory Strategy & Leadership
Continue reading:
Why Regulatory Belongs in the C-Suite
When Is It Time for a Chief Regulatory Officer?
Risk-Based Regulatory Strategy
TPP as a Leadership Tool
